Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS)

• Published in: Expert review of clinical immunology Vol. 17; no. 11; p. 1163
• Main Author: Lambert, Michele P
• Format: Journal Article
• Language: English
• Published: England 02.11.2021
• Subjects: Apoptosis; Autoimmune Diseases; Autoimmune Lymphoproliferative Syndrome - diagnosis; Autoimmune Lymphoproliferative Syndrome - genetics; fas Receptor; Humans; Multicenter Studies as Topic; Receptors, Antigen, T-Cell, alpha-beta; T-Lymphocytes; ALPS; DNTs; autoimmune lymphoproliferative syndrome; ALPS-like disorders
• ISSN: 1744-8409
• DOI: 10.1080/1744666X.2021.1978842

Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of immune dysregulation characterized by derangements in first apoptosis signal-mediated apoptosis and elevations in CD3 TCRαβ CD4 CD8 'double negative' T cells. As our understanding of this pleomorphic disorder expands, the importance of molecular diagnosis is ever more apparent due to the growing number of disorders that may present with overlapping initial symptoms, but for which there is an ever-increasing list of therapeutic options. This review will cover the current understanding of the molecular biology and pathophysiology of ALPS as well as describe some of the overlapping syndromes in order to better demonstrate the importance of establishing the correct diagnosis. Going forward, international, multicenter collaboration to fully characterize ALPS and the ALPS-like disorders, including with particular focus on defining the defects for those patients with undefined ALPS, is important to both continue to improve our understanding of this disorder and to drive patient care forward to provide the best outcomes. Additionally, it is probably time to re-convene an international expert panel to re-define diagnostic criteria taking into consideration the most recent available data in order to optimize patient care.